Publications

ChAdOx1 nCoV-19 (AZD1222) vaccine-induced Fc receptor binding tracks with differential susceptibility to COVID-19.

Kaplonek P. et al, (2023), Nature immunology

ChAdOx1 COVID vaccines express RBD open prefusion SARS-CoV-2 spikes on the cell surface

Zhang P. et al, (2023)

Immunization with matrix-, nucleoprotein and neuraminidase protects against H3N2 influenza challenge in pH1N1 pre-exposed pigs.

Vatzia E. et al, (2023), NPJ Vaccines, 8

ChAdOx1 NiV vaccination protects against lethal Nipah Bangladesh virus infection in African green monkeys.

van Doremalen N. et al, (2022), NPJ vaccines, 7

Lessons from the pandemic: Responding to emerging zoonotic viral diseases-a Keystone Symposia report.

Cable J. et al, (2022), Annals of the New York Academy of Sciences

Production of a high purity, C‐tagged hepatitis B surface antigen fusion protein VLP vaccine for malaria expressed in Pichia pastoris under cGMP conditions

Mukhopadhyay E. et al, (2022), Biotechnology and Bioengineering, 119, 2784 - 2793

ChAdOx1 nCoV-19 (AZD1222) or nCoV-19-Beta (AZD2816) protect Syrian hamsters against Beta Delta and Omicron variants

van Doremalen N. et al, (2022), Nature Communications, 13

Immunogenicity of High-Dose MVA-Based MERS Vaccine Candidate in Mice and Camels

Alharbi NK. et al, (2022), Vaccines, 10

Vaccines based on the replication-deficient simian adenoviral vector ChAdOx1: Standardized template with key considerations for a risk/benefit assessment.

Folegatti PM. et al, (2022), Vaccine, 40, 5248 - 5262

An exploratory analysis of the response to ChAdOx1 nCoV-19 (AZD1222) vaccine in males and females

Marchevsky NG. et al, (2022), eBioMedicine, 81, 104128 - 104128

Efficacy and safety of a universal influenza A vaccine (MVA-NP+M1) in adults when given after seasonal quadrivalent influenza vaccine immunisation (FLU009): a phase 2b, randomised, double-blind trial.

Evans TG. et al, (2022), The Lancet. Infectious diseases, 22, 857 - 866

Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV

Ogbe A. et al, (2022), JCI Insight, 7

Detection and quantification of antibody to SARS CoV 2 receptor binding domain provides enhanced sensitivity, specificity and utility

Rosadas C. et al, (2022), Journal of Virological Methods, 302, 114475 - 114475

CMV-associated T cell and NK cell terminal differentiation does not affect immunogenicity of ChAdOx1 vaccination

Sharpe HR. et al, (2022), JCI Insight, 7

The ChAdOx1 vectored vaccine, AZD2816, induces strong immunogenicity against SARS-CoV-2 beta (B.1.351) and other variants of concern in preclinical studies

Spencer AJ. et al, (2022), eBioMedicine, 77, 103902 - 103902

Efficacy of ChAdOx1 vaccines against SARS-CoV-2 Variants of Concern Beta, Delta and Omicron in the Syrian hamster model.

van Doremalen N. et al, (2022), Res Sq

The Combined Expression of the Nonstructural Protein NS1 and the N-Terminal Half of NS2 (NS21-180) by ChAdOx1 and MVA Confers Protection against Clinical Disease in Sheep upon Bluetongue Virus Challenge.

Utrilla-Trigo S. et al, (2022), Journal of virology, 96

Manufacturing a chimpanzee adenovirus-vectored SARS-CoV-2 vaccine to meet global needs.

Joe CCD. et al, (2022), Biotechnology and bioengineering, 119, 48 - 58

Safety and immunogenicity of ChAdOx1 MERS vaccine candidate in healthy Middle Eastern adults (MERS002): an open-label, non-randomised, dose-escalation, phase 1b trial

Bosaeed M. et al, (2022), The Lancet Microbe, 3, e11 - e20

ChAdOx1 nCoV-19 protection against SARS-CoV-2 in rhesus macaque and ferret challenge models

Lambe T. et al, (2021), Communications Biology, 4

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil

Clemens SAC. et al, (2021), Nature Communications, 12

Heterologous vaccination regimens with self-amplifying RNA and adenoviral COVID vaccines induce robust immune responses in mice

Spencer AJ. et al, (2021), Nature Communications, 12

Ultra-low dose immunization and multi-component vaccination strategies enhance protection against malaria in mice

Collins KA. et al, (2021), Scientific Reports, 11

Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection

Feng S. et al, (2021), Nature Medicine, 27, 2032 - 2040

ChAdOx1 nCoV-19 (AZD1222) protects Syrian hamsters against SARS-CoV-2 B.1.351 and B.1.1.7.

Fischer RJ. et al, (2021), Nature communications, 12

No one is safe until we are all safe

Gilbert S. and Hatchett R., (2021), Science Translational Medicine, 13

Recombinant protein vaccines against SARS-CoV-2.

Gilbert SC. and Lambe T., (2021), The Lancet. Infectious diseases, 21, 1337 - 1338

Durability of ChAdOx1 nCov-19 (AZD1222) vaccination in people living with HIV - responses to SARS-CoV-2, variants of concern and circulating coronaviruses

Ogbe A. et al, (2021)

Achieving global equity for COVID-19 vaccines: Stronger international partnerships and greater advocacy and solidarity are needed

Figueroa JP. et al, (2021), PLOS Medicine, 18, e1003772 - e1003772

Immunological and pathological outcomes of SARS-CoV-2 challenge following formalin-inactivated vaccine in ferrets and rhesus macaques

Bewley KR. et al, (2021), Science Advances, 7

Global public health security and justice for vaccines and therapeutics in the COVID-19 pandemic.

Hotez PJ. et al, (2021), EClinicalMedicine, 39

Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)

Flaxman A. et al, (2021), The Lancet, 398, 981 - 990

Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial

Madhi SA. et al, (2021), The Lancet HIV, 8, e568 - e580

Efficacy and Safety of a Modified Vaccinia Ankara-NP+M1 Vaccine Combined with QIV in People Aged 65 and Older: A Randomised Controlled Clinical Trial (INVICTUS)

Butler C. et al, (2021), Vaccines, 9, 851 - 851

Intranasal ChAdOx1 nCoV-19/AZD1222 vaccination reduces viral shedding after SARS-CoV-2 D614G challenge in preclinical models.

van Doremalen N. et al, (2021), Science translational medicine, 13

Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial

Frater J. et al, (2021), The Lancet HIV, 8, e474 - e485

Transcriptomic profiling of dromedary camels immunised with a mers vaccine candidate

Hala S. et al, (2021), Veterinary Sciences, 8

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil; an exploratory analysis of a randomised controlled trial

Clemens SC. et al, (2021)

Operation Warp Speed: implications for global vaccine security.

Lancet Commission on COVID-19 Vaccines and Therapeutics Task Force Members None., (2021), The Lancet. Global health, 9, e1017 - e1021

ChAdOx1 nCoV-19 (AZD1222) protects Syrian hamsters against SARS-CoV-2 B.1.351 and B.1.1.7.

Fischer RJ. et al, (2021), bioRxiv

Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection

Feng S. et al, (2021)

The ChAdOx1 vectored vaccine, AZD2816, induces strong immunogenicity against SARS-CoV-2 Beta (B.1.351) and other variants of concern in preclinical studies

Spencer AJ. et al, (2021)

Beyond the jab: A need for global coordination of pharmacovigilance for COVID-19 vaccine deployment.

Naniche D. et al, (2021), EClinicalMedicine, 36

Author Correction: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses

Barrett JR. et al, (2021), Nature Medicine, 27, 1113 - 1113

Author Correction: T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial

Ewer KJ. et al, (2021), Nature Medicine, 27, 1116 - 1116

Urgent needs to accelerate the race for COVID-19 therapeutics.

Batista C. et al, (2021), EClinicalMedicine, 36

Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant

Madhi SA. et al, (2021), New England Journal of Medicine, 384, 1885 - 1898

ChAdOx1 nCoV-19 (AZD1222) vaccine candidate significantly reduces SARS-CoV-2 shedding in ferrets.

Marsh GA. et al, (2021), NPJ vaccines, 6

Antibody evasion by the P.1 strain of SARS-CoV-2

Dejnirattisai W. et al, (2021), Cell, 184, 2939 - 2954.e9

Native-like SARS-CoV-2 Spike Glycoprotein Expressed by ChAdOx1 nCoV-19/AZD1222 Vaccine.

Watanabe Y. et al, (2021), ACS central science, 7, 594 - 602

Cookies on this website

Publications